MX2010006724A - Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. - Google Patents

Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.

Info

Publication number
MX2010006724A
MX2010006724A MX2010006724A MX2010006724A MX2010006724A MX 2010006724 A MX2010006724 A MX 2010006724A MX 2010006724 A MX2010006724 A MX 2010006724A MX 2010006724 A MX2010006724 A MX 2010006724A MX 2010006724 A MX2010006724 A MX 2010006724A
Authority
MX
Mexico
Prior art keywords
treatment
therapeutic regimens
immunoinflammatory disorders
subject
dipyridamole
Prior art date
Application number
MX2010006724A
Other languages
English (en)
Spanish (es)
Inventor
Mahesh V Padval
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of MX2010006724A publication Critical patent/MX2010006724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010006724A 2007-12-17 2008-12-17 Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. MX2010006724A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1430707P 2007-12-17 2007-12-17
PCT/US2008/013805 WO2009078998A1 (en) 2007-12-17 2008-12-17 Therapeutic regimens for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
MX2010006724A true MX2010006724A (es) 2010-09-07

Family

ID=40795828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006724A MX2010006724A (es) 2007-12-17 2008-12-17 Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.

Country Status (11)

Country Link
US (1) US20110189293A1 (enExample)
EP (1) EP2231129A4 (enExample)
JP (1) JP2011506607A (enExample)
KR (1) KR20100121601A (enExample)
CN (1) CN101938996A (enExample)
AU (1) AU2008338980A1 (enExample)
CA (1) CA2709561A1 (enExample)
IL (1) IL206435A0 (enExample)
MX (1) MX2010006724A (enExample)
NZ (1) NZ586332A (enExample)
WO (1) WO2009078998A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
CA2975000A1 (en) * 2015-01-28 2016-08-04 Realinn Life Science Limited Compounds for enhancing ppar.gamma. expression and nuclear translocation and therapeutic use thereof
CN106994128A (zh) * 2016-01-26 2017-08-01 上海普瑞得生物技术有限公司 17-α羟孕酮化合物在预防和治疗中性粒细胞炎症疾病中的应用
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
EP4427752A1 (en) * 2023-03-09 2024-09-11 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Dipyridamole as a novel therapy for muscular myogenesis disorders and inflammatory arthritis

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
AU496759B2 (en) * 1972-12-27 1978-10-26 Schering Aktiengesellschaft New pregnan-21-oic derivatives
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4107306A (en) * 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
US3934036A (en) * 1975-01-23 1976-01-20 Kyorin Seiyaku Kabushiki Kaisha N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent
EP0005911B1 (en) * 1978-05-26 1982-02-17 Imperial Chemical Industries Plc Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
BG36086A1 (en) * 1982-01-19 1984-09-14 Glbov Method for inducing interferon
US4879119A (en) * 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4554271A (en) * 1984-02-24 1985-11-19 The Upjohn Company Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
US5242921A (en) * 1988-04-27 1993-09-07 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
EG20321A (en) * 1993-07-21 1998-10-31 Otsuka Pharma Co Ltd Medical material and process for producing the same
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6235706B1 (en) * 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1225901A2 (en) * 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
EP1233768A1 (en) * 1999-11-15 2002-08-28 Smithkline Beecham Carvedilol methanesulfonate
US20010007083A1 (en) * 1999-12-29 2001-07-05 Roorda Wouter E. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
ES2330837T3 (es) * 2001-07-09 2009-12-16 Combinatorx, Incorporated Combinaciones para el tratamiento de trastornos inflamatorios.
GB0119848D0 (en) * 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
DE60239558D1 (de) * 2001-10-05 2011-05-05 Zalicus Inc Kombinationen für die behandlung von immun-entzündlichen erkrankungen
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
WO2004060354A1 (en) * 2002-12-31 2004-07-22 Augsburger Larry L Methods for making pharmaceutical dosage forms containing active cushioning components
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
JP4532868B2 (ja) * 2003-09-22 2010-08-25 キヤノン株式会社 放射線画像処理装置
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1999626A4 (en) * 2006-01-26 2009-11-25 Combinatorx Inc METHODS, COMPOSITIONS AND NEEDS FOR TREATING MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH
AU2007211101B2 (en) * 2006-01-27 2013-05-02 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CA2644889A1 (en) * 2006-03-07 2007-09-13 Combinatorx, Incorporated Compositions and methods for the treatment of immunoinflammatory disorders
US20090075955A1 (en) * 2007-09-19 2009-03-19 Combinatorx, Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
CA2709561A1 (en) 2009-06-25
WO2009078998A1 (en) 2009-06-25
NZ586332A (en) 2012-07-27
AU2008338980A1 (en) 2009-06-25
KR20100121601A (ko) 2010-11-18
US20110189293A1 (en) 2011-08-04
EP2231129A4 (en) 2013-01-30
EP2231129A1 (en) 2010-09-29
IL206435A0 (en) 2010-12-30
JP2011506607A (ja) 2011-03-03
CN101938996A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
WO2011146777A3 (en) Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2020002465A (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior.
NZ604029A (en) Methods of treating bladder cancer
WO2006102596A3 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
GB201111485D0 (en) Drug composition and its use in therapy
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
IN2014KN00996A (enExample)
MY173215A (en) Acetylcysteine compositions and methods of use thereof
NZ609201A (en) Means and methods for treating dlbcl
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
FI20135152A7 (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
MX359672B (es) Metodo para manejo de dolor cronico y tratamiento usando hcg.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal